Elizabeth Duperret

home / authors / elizabeth-duperret

Articles

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

Erika P. Hamilton, MD;Rinath M. Jeselsohn;Sara A. Hurvitz, MD;Dejan Juric;Hyo S Han;Melinda L. Telli, MD;George Zahrah;Rita Nanda, MD;Yuanyuan Zhang;Weiwei Tan;Elizabeth Duperret;Eric Zhi;Cecile Mather;Anne F. Schott, MD
August 10th 2024
22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

Sara A. Hurvitz, MD;Anne F. Schott, MD;Cynthia X. Ma, MD, PhD;Rita Nanda, MD;George Zahrah;Natasha Hunter, MD;Antoinette R. Tan;Melinda L. Telli, MD;Jesus Anampa Mesias;Rinath M. Jeselsohn;Pamela N. Munster, MD;Eric Zhi;Elizabeth Duperret;Cecile Mather;Erika P. Hamilton, MD;Hyo S Han
August 4th 2024

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
Published: May 17th 2013 | Updated: September 21st 2024
Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
NSCLC Patient Develops Fever and Rash Following Treatment for Brain Metastases
Published: July 31st 2012 | Updated: September 21st 2024
NSCLC Patient Develops Fever and Rash Following Treatment for Brain Metastases
What Caused The Mass in This 28-Year-Old's Neck?
Published: November 7th 2018 | Updated: September 21st 2024
What Caused The Mass in This 28-Year-Old's Neck?